Qomel Company vs Al Razi Medical Company
A head-to-head of Qomel Company (9600) and Al Razi Medical Company (9572) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | 9600 | 9572 |
|---|---|---|
| Market Cap | 343.14M SAR | 43.05M SAR |
| P/E (TTM) | 22.46 | 58.85 |
| Forward P/E | — | — |
| P/S | 2.60 | 0.58 |
| P/B | 2.80 | 2.06 |
| EV/EBITDA | 17.95 | 16.74 |
| Dividend Yield | — | — |
| Profit Margin | 11.31% | 1.10% |
| Gross Margin | 30.03% | 25.94% |
| Operating Margin | 15.88% | 2.65% |
| Revenue Growth (YoY) | -7.10% | +34.00% |
| FCF Yield | — | — |
| Debt / Equity | 32.12 | 11.78 |
| Current Ratio | 2.31 | 1.47 |
Which is better: Qomel Company or Al Razi Medical Company?
- ✓Larger by market cap: Qomel Company
- ✓Cheaper valuation (lower P/E): Qomel Company
- ✓More profitable (net margin): Qomel Company
- ✓Faster revenue growth: Al Razi Medical Company
Very close — each leads on 5 metrics.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Qomel Company with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.